{"id":"W4385651241","doi":"10.1016/s2352-3018(23)00136-4","title":"Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial","year":2023,"lang":"en","type":"article","venue":"The Lancet HIV","topic":"HIV/AIDS drug development and treatment","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":false,"ca_institutions":"University Health Network","funders":"ViiV Healthcare","keywords":"Emtricitabine; Rilpivirine; Medicine; Tenofovir alafenamide; Dolutegravir; Internal medicine; Population; Tolerability; Adverse effect; Human immunodeficiency virus (HIV); Virology; Viral load; Antiretroviral therapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002468229,0.0004953065,0.00185435,0.0002246288,0.0002417376,0.0001151019,0.0003799618,0.0001470187,0.00001000996],"category_scores_gemma":[0.001530316,0.0003036303,0.00006856694,0.0007248638,0.0001608803,0.0002045092,0.0004703349,0.0005562578,0.00001028465],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001756868,"about_ca_system_score_gemma":0.0002541704,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003722864,"about_ca_topic_score_gemma":0.00101827,"domain_scores_codex":[0.9965833,0.0003440182,0.00106871,0.0008320435,0.0004439305,0.0007280358],"domain_scores_gemma":[0.9965469,0.001989795,0.0003694622,0.0007103609,0.0001073053,0.0002761577],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9552899,0.0009178498,0.01622205,0.0001370339,0.0002426204,0.0003753097,0.007278346,0.00008950594,0.002147209,0.00001054195,0.0002067763,0.01708287],"study_design_scores_gemma":[0.8321474,0.002718316,0.1587528,0.0008066925,0.0002774317,0.00002007834,0.0005062458,0.003372513,0.000547858,0.00001914308,0.0004391378,0.0003923305],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874496,0.00008839669,0.0001961823,0.005448779,0.0001193939,0.005561735,0.0001604236,0.0001166815,0.0008587714],"genre_scores_gemma":[0.9965785,0.0002527845,0.001706075,0.00008463312,0.0001737372,0.000194998,0.0002286166,0.00004324064,0.0007374454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1425308,"threshold_uncertainty_score":0.9999416,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03948339338740951,"score_gpt":0.3262576267493967,"score_spread":0.2867742333619872,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}